Evidence map›Paper›PMID 28520704›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2017

Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study.

Yang Zhang, Shanshan Wu, Yinyin Xia, Ni Wang, Lin Zhou, Jing Wang, Renfei Fang, Feng Sun, Mingting Chen, Siyan Zhan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Trial
  6. Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2020
    Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yang ZhangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China (mainland).
Shanshan WuNational Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China (mainland).
Yinyin XiaNational Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (mainland).
Ni WangNational Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (mainland).
Lin ZhouNational Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (mainland).
Jing WangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China (mainland).
Renfei FangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China (mainland).
Feng SunDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China (mainland).
Mingting ChenNational Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (mainland).
Siyan ZhanDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China (mainland).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Adverse events are under-appreciated negative consequences that are significant clinical problems for patients undergoing anti-MDR-TB treatment due to longer duration of treatment and more need for concurrent use of multiple second-line drugs. The aim of this study was to determine the incidence of adverse events and their impact on MDR-TB therapy and treatment outcome, and to identify possible drug-event pairs in China. MATERIAL AND METHODS An ambispective cohort study was conducted based on hospital medical records, which included a retrospective study that enrolled 751 MDR-TB patients receiving standardized regimen between May 2009 and July 2013, and a follow-up investigation of treatment outcome conducted in December 2016 in China. Adverse events were determined according to laboratory results or clinical criteria. Cox's proportional hazards regression models were used for evaluating associations. RESULTS There were 681(90.7%) patients experienced at least 1 type of adverse event and 55.2% of them required a changed MDR-TB treatment; 51(6.8%) patients required permanent discontinuation of the offending drug due to adverse events. The occurrence of adverse events was associated with poor treatment outcome (adjusted hazard ratio, 1.54; 95% CI 1.21, 1.87). A total of 10 different drug-event pairs were identified. CONCLUSIONS Adverse events occurred commonly during MDR-TB treatment in China, and often resulted in MDR-TB treatment change. The occurrence of adverse events affected MDR-TB poor outcome after treatment.

Indexed as

AdultAntitubercular AgentsChinaCohort StudiesDrug-Related Side Effects and Adverse ReactionsDrug Resistance, Multiple, BacterialFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeTuberculosisTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID28520704
PMCPMC5444822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.